Adagene, Inc. (ADAG)
3.84
+0.02
(+0.52%)
USD |
NASDAQ |
Aug 26, 13:35
Adagene Enterprise Value : 343.77M for Aug. 25, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| August 25, 2026 | 343.77M |
| August 24, 2026 | 349.14M |
| August 21, 2026 | 357.20M |
| August 20, 2026 | 361.90M |
| August 19, 2026 | 363.91M |
| August 18, 2026 | 359.21M |
| August 17, 2026 | 344.44M |
| August 14, 2026 | 335.71M |
| August 13, 2026 | 337.05M |
| August 12, 2026 | 339.07M |
| August 11, 2026 | 348.47M |
| August 10, 2026 | 360.55M |
| August 07, 2026 | 363.24M |
| August 06, 2026 | 365.25M |
| August 05, 2026 | 371.30M |
| August 04, 2026 | 331.68M |
| August 03, 2026 | 331.01M |
| July 31, 2026 | 339.07M |
| July 30, 2026 | 337.72M |
| July 29, 2026 | 337.05M |
| July 28, 2026 | 337.72M |
| July 27, 2026 | 324.30M |
| July 24, 2026 | 302.14M |
| July 23, 2026 | 313.55M |
| July 22, 2026 | 327.65M |
| Date | Value |
|---|---|
| July 21, 2026 | 334.37M |
| July 20, 2026 | 330.34M |
| July 17, 2026 | 328.32M |
| July 16, 2026 | 327.65M |
| July 15, 2026 | 333.70M |
| July 14, 2026 | 329.67M |
| July 13, 2026 | 343.77M |
| July 10, 2026 | 351.82M |
| July 09, 2026 | 345.78M |
| July 08, 2026 | 344.44M |
| July 07, 2026 | 351.15M |
| July 06, 2026 | 351.15M |
| July 02, 2026 | 387.41M |
| July 01, 2026 | 408.22M |
| June 30, 2026 | 369.28M |
| June 29, 2026 | 287.72M |
| June 26, 2026 | 285.83M |
| June 25, 2026 | 282.51M |
| June 24, 2026 | 288.67M |
| June 23, 2026 | 275.87M |
| June 22, 2026 | 269.24M |
| June 18, 2026 | 273.98M |
| June 17, 2026 | 254.55M |
| June 16, 2026 | 253.60M |
| June 15, 2026 | 259.76M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Ascletis Pharma, Inc. | 1.194B |
| CStone Pharmaceuticals Co. Ltd. | 804.85M |
| RemeGen Co., Ltd. | 5.080B |
| InnoCare Pharma Ltd. | 1.833B |
| JW (Cayman) Therapeutics Co. Ltd. | -- |
Enterprise Value Related Metrics
| Earnings Yield | -9.83% |
| Normalized Earnings Yield | -9.531 |